
J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports
Summary
Healthcare giant Johnson and Johnson is reportedly in discussions to acquire the specialized biotechnology company Ollin. The potential transaction value is estimated to reach billions of dollars according to recent media reports.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.